2-Amino-6-pyrrolidino-nebularin | 36799-22-1

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2-Amino-6-pyrrolidino-nebularin
• 英文别名: 1-(2-amino-6-pyrrolidin-1-yl-purin-9-yl)-β-D-1-deoxy-ribofuranose；N6,N6-tetramethylene-2-aminoadenosine；2-amino-6-(1-pyrrolidinyl)-9-(β-D-ribofuranosyl)purine；2-amino-6-(1-pyrrolidinyl)-9-(beta-D-ribofuranosyl)purine；(2R,3R,4S,5R)-2-(2-amino-6-pyrrolidin-1-ylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 36799-22-1
• 化学式: C₁₄H₂₀N₆O₄
• 分子量: 336.351
• InChiKey: MMLLIIYCNPDYJQ-QYVSTXNMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  143
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  四氢吡咯 、 鸟苷 在 氯化锌 作用下， 以 甲醇 、 三甲基氯硅烷 为溶剂， 生成 2-Amino-6-pyrrolidino-nebularin
  参考文献：
  名称：

  N.sup.6 -substituted adenosines

  摘要：

  N.sup.6-取代腺苷类新化合物及从6-三烷基硅氧基嘌呤衍生物制备N.sup.6-取代腺苷类化合物的新方法。这些衍生物在三级碱或Lewis酸存在下与氨或HNR.sub.1 R.sub.2（其中R.sub.1和R.sub.2相同或不同，代表氢、1-6碳原子的烷基、7-10碳原子的芳基或未取代或取代的含有氢氧基或1-4碳原子的烷氧基的芳基，未取代或取代的含有氢氧基或1-4碳原子的烷氧基的芳基，含有1-3个杂原子的4-7环的杂环，这些杂原子可以是氮、氧或硫；或者当R.sub.1为氢时，R.sub.2为羟基、氨基、1-4碳原子的末端取代为单烷基氨基团的烷基，每个烷基团中含有1-4碳原子，或含有1-3个杂原子的5-10环的单烷基或双环杂环基，这些杂原子可以是氮、氧和硫，或R.sub.1和R.sub.2与N原子一起共同代表含有1-3个杂原子的4-7环的杂单环环，除氮原子外，这些杂原子可以是氮、氧或硫，未取代或取代为含有1-4碳原子的烷基。该发明的化合物具有诸如细胞激素等有价值的生物学性质。

  公开号：

  US03983104A1

文献信息

• Anti-HCV nucleoside derivatives
  申请人：——

  公开号：US20030008841A1

  公开（公告）日：2003-01-09

  The present invention comprises novel and known purine and pyrimidine nucleoside derivatives which have been discovered to be active against hepatitis C virus (HCV). The use of these derivatives for the treatment of HCV infection is claimed as are the novel nucleoside derivatives disclosed herein.

  本发明涉及新颖和已知的嘌呤和嘧啶核苷衍生物，已发现这些衍生物对丙型肝炎病毒（HCV）具有活性。本发明声明利用这些衍生物治疗HCV感染，以及本文所披露的新颖核苷衍生物。
• NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1315736A2

  公开（公告）日：2003-06-04
• [EN] NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C<br/>[FR] DERIVES DE NUCLEOSIDES
  申请人：——

  公开号：WO2002018404A9

  公开（公告）日：2003-10-02

  [EN] Use of compounds of formula (I), wherein R<1> is hydrogen, hydroxy, alkyl, hydroxyalkyl, alkoxy, halogen, cyano, isocyano or azido; R<2> is hydrogen, hydroxy, alkoxy, chlorine, bromine or iodine; R<3> is hydrogen; or R<2> and R<3> together represent =CH2; or R<2> and R<3> represent fluorine; X is O, s or CH2; a, b, c, d denoting asymmetric carbon atoms each of which is substituted with 4 different substituents; and B signifies a purine base B1 which is connected through the 9-nitrogen of formula (B1), wherein R<4> is hydrogen, hydroxyl, alkyl, alkoxy, alkylthio, aryloxy, arylthio, heterocyclyl, NR<7>R<8>, halogen or SH; R<5> is hydrogen, hydroxy, alkyl, haloalkyl, cycloalkyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, heterocyclyl, heterocyclylamino, halogen, NR<7>R<8>, NHOR<9>, NHNR<7>R<8> or SH; R<6> is hydrogen, hydroxy, alkyl, alkoxy, alkylthio, aryloxy, arylthio, heterocyclyl, NR<7>R<8>, halogen, SH or cyano; R<7> and R<8> are independently of each other hydrogen, alkyl, aryl, hydroxyalkyl, alkenylalkyl, alkynylalkyl, cycloalkyl or acyl; R<9> is hydrogen, alkyl or aryl; or B signifies an oxidised purine base B2 which is connected through the 9-nitrogen of formula (B2), wherein R<4>, R<5> and R<6> are as defined above; or B signifies a purine base B3 which is connected through the 9-nitrogen of formula (B3), wherein R<4> and R<6> are as defined above; R<10> is hydrogen, alkyl or aryl; Y is O, S or NR<11>; R<11> is hydrogen, hydroxy, alkyl, OR<9>, heterocyclyl or NR<7>R<8>; R<7>, R<8> and R<9> are as defined above; or B signifies a pyrimidine base B4 which is connected through the 1-nitrogen of formula (B4), wherein Z is O or S; R<12> is hydrogen, hydroxy, alkyl, alkoxy, haloalkyl, alkylthio, aryl, aryloxy, arylthio, heterocyclyl, heterocyclylamino, halogen, NR<7>R<8>, NHOR<9>, NHNR<7>R<8> or SH; R<13> is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, cycloalkyl or halogen; R<7>, R<8> and R<9> are as defined above; or B signifies a pyrimidine base B5 which is connected through the 1-nitrogen of formula (B5), wherein Y, Z, R<10> are as defined above for the treatment of diseases mediated by the Hepatitis C Virus (HIV) or for the preparation of a medicament for such treatment. The invention is concerned with novel and known purine and pyrimidine nucleoside derivatives, their use as inhibitors of subgenomic Hepatitis C Virus (HCV) RNA replication and pharmaceutical compositions of such compounds.
  [FR] L'invention concerne l'utilisation de composés représentés par la formule (I), dans laquelle R<1> représente hydrogène, hydroxy, alkyle, hydroxyalkyle, alcoxy, halogène, cyano, isocyano ou azido; R<2> représente hydrogène, hydroxy, alcoxy, chlore, brome ou iode; R<3> représente hydrogène; ou R<2> et R<3> représentent ensemble =CH2; ou R<2> et R<3> représentent fluor; X représente O, S ou CH2; a, b, c, d représentant des atomes de carbone asymétriqued dont chacun est subtitué avec 4 substituants différents; et B représente une base purique B1 qui est reliée au moyen du 9-azote représenté par la formule (B1), dans laquelle R<4> représente hydrogène, hydroxy, alkyle, alcoxy, alkylthio, aryloxy, arylthio, hétérocyclyle, NR<7>R<8>, halogène ou SH; R<5> représente hydrogène, hydroxy, alkyle, haloalkyle, cycloalkyle, alcoxy, alkylthio, aryle, aryloxy, arylthio, hétérocyclyle, hétérocyclylamino, halogène, NR<7>R<8>, NHOR<9>, NHNR<7>R<8> ou SH; R<6> représente hydrogène, hydroxy, alkyle, alcoxy, alkylthio, aryloxy, arylthio, hétérocyclyle, NR<7>R<8>, halogène, SH ou cyano; R<7> et R<8> représentent independamment l'un de l'autre hydrogène, alkyle, aryle, hydroxyalkyle, alcénylalkyle, alkynylalkyle, cycloalkyle ou acyle; R<9> représente hydrogène, alkyle ou aryle; ou B représente une base purique oxydée B2 qui est reliée au moyen du 9-azote représenté par la formule (B2), dans laquelle R<4>, R<5> et R<6> sont tels que définis ci-dessus; ou B représente une base purique B3 qui est reliée au moyen du 9-azote représenté par la formule (B3), dans laquelle R<4> et R<6> sont tels que définis ci-dessus; R<10> représente hydrogène, alkyle ou aryle; Y représente O, S ou NR<11>; R<11> représente hydrogène, hydroxy, alkyle, OR<9>, hétérocyclyle ou NR<7>R<8>; R<7>, R<8> et R<9> sont tels que définis ci-dessus; ou B représente une base pyrimidique B4 qui est reliée au moyen du 1-azote représenté par la formule (B4), dans laquelle Z représente O ou S; R<12> représente hydrogène, hydroxy, alkyle, alcoxy, haloalkyle, alkylthio, aryle, aryloxy, arylthio, hétérocyclyle, hétérocyclylamino, halogène, NR<7>R<8>, NHOR<9>, NHNR<7>R<8> ou SH; R<13> représente hydrogène, alkyle, hydroxyalkyle, alcoxyalkyle, haloalkyle, cycloalkyle ou halogène; R<7>, R<8> et R<9> sont tels que définis ci-dessus; ou B représente une base pyrimidique B5 qui est reliée au moyen du 1-azote représenté par la formule (B5), dans laquelle Y, Z, R<10> et R13 sont tels que définis ci-dessus, pour le traitement de maladies à médiation du virus de l'hépatite C (VHC) ou pour la préparation d'un médicament pour un tel traitement. L'invention concerne des dérivés de nucléosides puriques et pyrimidiques connus et nouveaux, ainsi que leur utilisation en tant qu'inhibiteur de la réplication de l'ARN du virus de l'hépatite C (VHC) subgénomique et des compositions pharmaceutiques de tels composés.
• [EN] NUCLEOSIDE DERIVATIVES<br/>[FR] DERIVES DE NUCLEOSIDES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2002018404A2

  公开（公告）日：2002-03-07

  Use of compounds of formula (I), wherein R1 is hydrogen, hydroxy, alkyl, hydroxyalkyl, alkoxy, halogen, cyano, isocyano or azido; R2 is hydrogen, hydroxy, alkoxy, chlorine, bromine or iodine; R3 is hydrogen; or R?2 and R3¿ together represent =CH¿2?; or R?2 and R3¿ represent fluorine; X is O, s or CH¿2?; a, b, c, d denoting asymmetric carbon atoms each of which is substituted with 4 different substituents; and B signifies a purine base B1 which is connected through the 9-nitrogen of formula (B1), wherein R?4¿ is hydrogen, hydroxyl, alkyl, alkoxy, alkylthio, aryloxy, arylthio, heterocyclyl, NR7R8, halogen or SH; R5 is hydrogen, hydroxy, alkyl, haloalkyl, cycloalkyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, heterocyclyl, heterocyclylamino, halogen, NR?7R8, NHOR9, NHNR7R8¿ or SH; R6 is hydrogen, hydroxy, alkyl, alkoxy, alkylthio, aryloxy, arylthio, heterocyclyl, NR7R8, halogen, SH or cyano; R?7 and R8¿ are independently of each other hydrogen, alkyl, aryl, hydroxyalkyl, alkenylalkyl, alkynylalkyl, cycloalkyl or acyl; R9 is hydrogen, alkyl or aryl; or B signifies an oxidised purine base B2 which is connected through the 9-nitrogen of formula (B2), wherein R?4, R5 and R6¿ are as defined above; or B signifies a purine base B3 which is connected through the 9-nitrogen of formula (B3), wherein R?4 and R6¿ are as defined above; R10 is hydrogen, alkyl or aryl; Y is O, S or NR11; R11 is hydrogen, hydroxy, alkyl, OR9, heterocyclyl or NR?7R8; R7, R8 and R9¿ are as defined above; or B signifies a pyrimidine base B4 which is connected through the 1-nitrogen of formula (B4), wherein Z is O or S; R12 is hydrogen, hydroxy, alkyl, alkoxy, haloalkyl, alkylthio, aryl, aryloxy, arylthio, heterocyclyl, heterocyclylamino, halogen, NR?7R8, NHOR9, NHNR7R8¿ or SH; R13 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, cycloalkyl or halogen; R?7, R8 and R9¿ are as defined above; or B signifies a pyrimidine base B5 which is connected through the 1-nitrogen of formula (B5), wherein Y, Z, R10 are as defined above for the treatment of diseases mediated by the Hepatitis C Virus (HIV) or for the preparation of a medicament for such treatment. The invention is concerned with novel and known purine and pyrimidine nucleoside derivatives, their use as inhibitors of subgenomic Hepatitis C Virus (HCV) RNA replication and pharmaceutical compositions of such compounds.
• N.sup.6 -substituted adenosines
  申请人：Schering Aktiengesellschaft

  公开号：US03983104A1

  公开（公告）日：1976-09-28

  Novel N.sup.6 -substituted adenosines and a novel process for the preparation of N.sup.6 -substituted adenosines from 6-trialkylsiloxypurine derivatives. The derivatives are reacted in the presence of a tertiary base or a Lewis acid with ammonia or an amine of the formula HNR.sub.1 R.sub.2, wherein R.sub.1 and R.sub.2 are the same or different represent hydrogen, alkyl of 1-6 carbon atoms, aralkyl or 7 to 10 carbon atoms unsubstituted or substituted with hydroxy or alkoxy with 1-4 carbon atoms, aryl unsubstituted or substituted with hydroxy or alkoxy with 1 to 4 carbon atoms, a heterocyclic ring of 4 to 7 members, containing a total of 1-3 hetero atoms which can be nitrogen, oxygen or sulfur; or when R.sub.1 is hydrogen R.sub.2 is hydroxyl, amino, alkyl of 1-4 carbon atoms substituted in the terminal position with a mono- or dialkylamino group, containing 1-4 carbon atoms in each alkyl group, or mono- or bicyclic heterocyclic group of 5-10 members, containing a total of 1-3 hetero atoms, which can be nitrogen, oxygen and sulfur, or R.sub.1 and R.sub.2, together with the N-atom, collectively represent a heteromonocyclic ring of 4-7 members containing a total of 1-3 hetero atoms which, in addition to the nitrogen atom, can be nitrogen, oxygen or sulfur, unsubstituted or substituted by an alkyl group with 1-4 carbon atoms. The compounds of the invention have valuable biological properties such as cytokinins, etc.

  N.sup.6-取代腺苷类新化合物及从6-三烷基硅氧基嘌呤衍生物制备N.sup.6-取代腺苷类化合物的新方法。这些衍生物在三级碱或Lewis酸存在下与氨或HNR.sub.1 R.sub.2（其中R.sub.1和R.sub.2相同或不同，代表氢、1-6碳原子的烷基、7-10碳原子的芳基或未取代或取代的含有氢氧基或1-4碳原子的烷氧基的芳基，未取代或取代的含有氢氧基或1-4碳原子的烷氧基的芳基，含有1-3个杂原子的4-7环的杂环，这些杂原子可以是氮、氧或硫；或者当R.sub.1为氢时，R.sub.2为羟基、氨基、1-4碳原子的末端取代为单烷基氨基团的烷基，每个烷基团中含有1-4碳原子，或含有1-3个杂原子的5-10环的单烷基或双环杂环基，这些杂原子可以是氮、氧和硫，或R.sub.1和R.sub.2与N原子一起共同代表含有1-3个杂原子的4-7环的杂单环环，除氮原子外，这些杂原子可以是氮、氧或硫，未取代或取代为含有1-4碳原子的烷基。该发明的化合物具有诸如细胞激素等有价值的生物学性质。